Drug intelligence / Profile preview

LICR-LON-Fib75 + abrin A-chain conjugate

Development stage: Discontinued
Lead developer: Ludwig Cancer Research
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics

Overview

LICR-LON-Fib75 + abrin A-chain conjugate is an early-stage experimental immunotoxin (antibody-drug conjugate) developed in the 1980s for antineoplastic purposes. It consists of the LICR-LON-Fib75 (also referred to as LICR-LOND-Fib75) mouse monoclonal antibody, which targets the cell surface glycoprotein CD59 expressed on human carcinoma cells, covalently linked to the A-chain of abrin, a ribosome-inactivating protein toxin derived from *Abrus precatorius*. The abrin A-chain is carbohydrate-free, which reduces hepatic uptake and potentially extends its circulatory half-life compared to ricin A-chain conjugates. This immunotoxin was investigated in academic and institutional settings, particularly for purging bone marrow of infiltrating breast cancer cells in patients undergoing high-dose chemotherapy (such as melphalan) followed by autologous bone marrow rescue. It has no known commercial developer and did not advance to clinical trials or regulatory approval.

Other names: LICR-LOND-Fib75 conjugated with abrin A-chainLICR-LOND-Fib-75 conjugated with abrin A-chainLICR-LOND-Fib 75 conjugated with abrin A-chainLICR-LOND-Fib75/abrin A-chain conjugateLICR-LON-Fib75/abrin A-chainLICR-LON-Fib75/abrin A-chain conjugate

Targets

CD59 (CD59 glycoprotein)

Beyond the preview

Go deeper on LICR-LON-Fib75 + abrin A-chain conjugate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LICR-LON-Fib75 + abrin A-chain conjugate.

Explore the full profile